Aptevo Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
APVO$1.08-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(in thousands)
| For the Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Activities | ||
| Net loss | $(25,967) | $(24,130) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 96 | 1,069 |
| Non-cash lease expense | 1,089 | 1,100 |
| Depreciation and amortization | 240 | 352 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 483 | 217 |
| Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease | (157) | (1,017) |
| Operating lease liability | (1,376) | (1,376) |
| Net cash used in operating activities | (25,592) | (23,785) |
| Investing Activities | ||
| Net cash from investing activities | — | — |
| Financing Activities | ||
| Value of equity awards withheld for tax liability | — | (1) |
| Proceeds from exercise of common warrants, net of issuance costs | 557 | 5,563 |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 37,940 | 10,036 |
| Payments in lieu of fractional shares | — | (3) |
| Net cash provided by financing activities | 38,497 | 15,595 |
| Increase (decrease) in cash and cash equivalents | 12,905 | (8,190) |
| Cash and cash equivalents at beginning of period | 8,714 | 16,904 |
| Cash and cash equivalents at end of period | $21,619 | $8,714 |
| Supplemental Cash Flow Information | ||
| Warrant modification - incremental value | $586 | $472 |
| Dividend attributable to down round feature of warrants | 1,571 | — |
| Fair value of December 2024 inducement transaction common warrants | $— | $7,331 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.